Trial Profile
A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2023
Price :
$35
*
At a glance
- Drugs CTX 712 (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Chordia Therapeutics
- 13 Dec 2022 Results (n=6; As of April 28, 2022) assessing the dose escalation cohort of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes, including preliminary efficacy results of CTX-712, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 07 Jun 2022 Results (As of Dec. 31, 2021, n=30 ) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2022 Interim Results published in the Chordia Therapeutics Media Release.